Amarin Corporation plc (ADR) (NASDAQ:AMRN), a pharmaceutical company with its main focus on development and commercialization of therapeutics to improve cardiovascular health, presented the result of a key Vitro study that showed pretreatment with EPA resulted in better endothelial function compared to other TG lowering agents. The presentation of the result was taken as a signal to book profits as the selling pressure in the last 2 sessions was intense. The daily range of $0.5-$0.6 in the last two session were the largest in more than a year and that took place with a big jump in volume, evident from the 35 million yesterday against the average volume of 10 million only.
The result of Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced last week was taken positively by the market as the net product revenue increased by 17% in the 4th quarter from $14.1 million to $16.5 million on a quarter on quarter basis and increased by a huge 105% to $54.2 million from the earlier $26.4 million on a year on year basis. Another encouraging figure came in the form of the earnings per share of $-0.57 against the expected $-0.59.
Technically, strong support can be expected from the two levels of $2.10 and then $1.80 at the lower levels. These two levels define the range that has acted as a major supply area in the past but now, following the breakout, it has turned into a demand zone. The sharp spike in the volume with the crash in price in the last two sessions implies a solid selloff and the bears may expect to continue the pressure but the key in the short term is the price action around $2.00. If reactive buyers are seen coming there, then the correction can end very fast and a bounce can’t be discarded then.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: